Related Experiment Video
Updated: Jul 6, 2025

Assessing Retinal Microglial Phagocytic Function In Vivo Using a Flow Cytometry-based Assay
Published on: October 18, 2016
VEGF controls microglial phagocytic response to amyloid-β
Priscille de Gea1, Sarah Benkeder1, Pauline Bouvet1
1Laboratory MeLIS, Institut Neuromyogène, Synaptopathies and Autoantibodies, INSERM U1314, CNRS UMR 5284, Université Claude Bernard Lyon 1, Lyon, France.
Abstract:
Microglial cells are well known to be implicated in the pathogenesis of Alzheimer's disease (AD), due to the impaired clearance of amyloid-β (Aβ) protein. In AD, Aβ accumulates in the brain parenchyma as soluble oligomers and protofibrils, and its aggregation process further give rise to amyloid plaques. Compelling evidence now indicate that Aβ oligomers (Aβo) are the most toxic forms responsible for neuronal and synaptic alterations. Recently, we showed that the Vascular Endothelial Growth Factor (VEGF) counteracts Aβo-induced synaptic alterations and that a peptide derived from VEGF is able to inhibit Aβ aggregation process. Moreover, VEGF has been reported to promote microglial chemotaxis to Aβ brain deposits. We therefore investigated whether VEGF could influence microglial phagocytic response to Aβ, using in vitro and ex vivo models of amyloid accumulation. We report here that VEGF increases Aβo phagocytosis by microglial cells and further characterized the molecular basis of the VEGF effect. VEGF is able to control α-secretase activity in microglial cells, resulting in the increased cleavage of the Triggering Receptor Expressed on Myeloid cells 2 (TREM2), a major microglial Aβ receptor. Consistently, the soluble form sTREM2 also increases Aβo phagocytosis by microglial cells. Taken together, these findings propose VEGF as a new regulator of Aβ clearance and suggest its potential role in rescuing compromised microglial function in AD.
Insights
Vascular Endothelial Growth Factor (VEGF) enhances microglial cells' ability to clear toxic amyloid-beta oligomers (Aβo) in Alzheimer's disease (AD). This discovery suggests VEGF could restore microglial function in AD.
Area of Science:
- Neuroscience
- Immunology
- Molecular Biology
Background:
- Microglial cells are crucial in Alzheimer's disease (AD) pathogenesis due to impaired amyloid-beta (Aβ) clearance.
- Amyloid-beta oligomers (Aβo) are the most neurotoxic forms, causing synaptic damage.
- Vascular Endothelial Growth Factor (VEGF) has shown potential in counteracting Aβo effects and promoting microglial migration.
Purpose of the Study:
- To investigate the influence of VEGF on microglial phagocytic response to Aβ.
- To elucidate the molecular mechanisms underlying VEGF's effect on microglial Aβ clearance.
Main Methods:
- Utilized in vitro and ex vivo models of amyloid accumulation.
- Assessed microglial phagocytosis of Aβ oligomers.
- Investigated the role of α-secretase activity and TREM2 cleavage in microglial cells.
Main Results:
- VEGF significantly increases the phagocytosis of Aβ oligomers by microglial cells.
- VEGF modulates α-secretase activity, leading to enhanced cleavage of TREM2 (Triggering Receptor Expressed on Myeloid cells 2).
- Soluble TREM2 (sTREM2) also promotes microglial phagocytosis of Aβ oligomers.
Conclusions:
- VEGF acts as a novel regulator of Aβ clearance by enhancing microglial phagocytosis.
- The findings suggest VEGF's potential therapeutic role in restoring impaired microglial function in Alzheimer's disease.

